Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Upgrade: Dedicated Screeners for Stocks & ETFs

Liminatus Pharma Inc.

Contributing Author

Recent Articles by Liminatus Pharma Inc.

Sep-29	Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule LIMN -8.43% GlobeNewswire
Aug-24	Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy LIMN -9.50% GlobeNewswire
Aug-18	Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock LIMN -8.06% LIMN -14.08% GlobeNewswire
Aug-13	Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement LIMN +38.16% GlobeNewswire
Jun-30	Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline LIMN GlobeNewswire
Jun-03	Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds LIMN -22.21% GlobeNewswire
May-21	Liminatus Pharma Announces Nasdaq Delisting Notification LIMN -31.14% GlobeNewswire
Mar-17	Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody LIMN GlobeNewswire
Feb-17	Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering LIMN -31.86% GlobeNewswire
Oct-30	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation LIMN GlobeNewswire
Jul-28	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative LIMN -7.23% GlobeNewswire
Jul-25	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies LIMN GlobeNewswire
Jul-24	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy LIMN +30.91% GlobeNewswire
Jul-22	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy LIMN LIMN +11.94% GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)